Table 1.

Second generation GPAs approved and/or in development [23].

Drug	GPA Precursor	Microbiological Spectrum	Main Clinical Indication	Status
Oritavancin (Orbactiv)	Chloroeremomycin	MRSA 1, VRSA 1, VRE 1	ABSSSI 2	approved by FDA 3 in 2014
Telavancin (Vibativ)	Vancomycin	MRSA 1, MSSA 1, VSE 1, Streptococcus pyogenes	cSSSI 2	approved by FDA 3 in 2009
		Staphylococcus aureus	HABP/VABP 2	approved by FDA 3 in 2013
Dalbavancin (Dalvance)	A40926	MRSA 1, MSSA 1, Streptococcus pyogenes	ABSSSI 2	approved by FDA 3 in 2014

¹ MRSA, methicillin-resistant Staphylococcus aureus; VRSA, vancomycin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; MSSA, methicillin-susceptible Staphylococcus aureus; VSE, vancomycin-susceptible enterococci; ² ABSSSI, acute bacterial skin and skin structure infections; cSSSI, complicated skin and skin structure infections; HABP/VABP, hospital-acquired and ventilator-associated bacterial pneumonia; ³ FDA, Food and Drug Administration.